Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?

被引:5
作者
Dilokthornsakul, Piyameth [1 ,2 ]
Chaiyakunapruk, Nathorn [1 ,3 ,4 ,5 ]
Campbell, Jonathan D. [2 ]
机构
[1] Naresuan Univ, Fac Pharmaceut Sci, Ctr Pharmaceut Outcomes Res, Dept Pharm Practice, Phitsanulok 65000, Thailand
[2] Univ Colorado, Ctr Pharmaceut Outcomes Res, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO USA
[3] Monash Univ Malaysia, Sch Pharm, Kuala Lumpur, Selangor, Malaysia
[4] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia
[5] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
关键词
Asthma; efficacy; effectiveness; cost-effectiveness analysis; LEUKOTRIENE RECEPTOR ANTAGONISTS; PERSISTENT ASTHMA; ALLERGIC-ASTHMA; INHALED CORTICOSTEROIDS; UNCONTROLLED ASTHMA; ECONOMIC-EVALUATION; UTILITY ANALYSIS; OMALIZUMAB; TRIAL; FLUTICASONE;
D O I
10.1080/02770903.2016.1193601
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Objective: To test the association of clinical evidence type, efficacy-based or effectiveness-based (E), versus whether or not asthma interventions' cost-effectiveness findings are favorable. Data sources: We conducted a systematic review of PubMed, EMBASE, Tufts CEA registry, Cochrane CENTRAL, and the UK National Health Services Economic Evaluation Database from 2009 to 2014. Study Selection: All cost-effectiveness studies evaluating asthma medication(s) were included. Clinical evidence type, E, was classified as efficacy-based if the evidence was from an explanatory randomized controlled trial(s) or meta-analysis, while evidence from pragmatic trial(s) or observational study(s) was classified as effectiveness-based. We defined three times the World Health Organization cost-effectiveness willingness-to-pay (WTP) threshold or less as a favorable cost-effectiveness finding. Logistic regression tested the likelihood of favorable versus unfavorable cost-effectiveness findings against the type of E. Results and conclusions: 25 cost-effectiveness studies were included. Ten (40.0%) studies were effectiveness-based, yet 15 (60.0%) studies were efficacy-based. Of 17 studies using endpoints that could be compared to WTP threshold, 7 out of 8 (87.5%) effectiveness-based studies yielded favorable cost-effectiveness results, whereas 4 out of 9 (44.4%) efficacy-based studies yielded favorable cost-effectiveness results. The adjusted odds ratio was 15.12 (95% confidence interval; 0.59 to 388.75) for effectiveness-based versus efficacy-based achieving favorable cost-effectiveness findings. More asthma cost-effectiveness studies used efficacy-based evidence. Studies using effectiveness-based evidence trended toward being more likely to disseminate favorable cost-effective findings than those using efficacy. Health policy decision makers should pay attention to the type of clinical evidence used in cost-effectiveness studies for accurate interpretation and application.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 33 条
[1]   A Cost-effectiveness Analysis of Dexamethasone Versus Prednisone in Pediatric Acute Asthma Exacerbations [J].
Andrews, Annie Lintzenich ;
Wong, Kelli A. ;
Heine, Daniel ;
Russell, W. Scott .
ACADEMIC EMERGENCY MEDICINE, 2012, 19 (08) :943-948
[2]  
[Anonymous], 2015, COST EFF STRAT PLANN
[3]  
Bond K, 2010, CADTH TECHNOL OVERV, V1, pe0120
[4]   Economic evaluation of BDP/formoterol fixed vs two single inhalers in asthma treatment [J].
Brueggenjuergen, B. ;
Ezzat, N. ;
Kardos, P. ;
Buhl, R. .
ALLERGY, 2010, 65 (09) :1108-1115
[5]   Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6-11 Years A NICE Single Technology Appraisal [J].
Burch, Jane ;
Griffin, Susan ;
McKenna, Claire ;
Walker, Simon ;
Paton, James ;
Wright, Kath ;
Woolacott, Nerys .
PHARMACOECONOMICS, 2012, 30 (11) :991-1004
[6]   The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective [J].
Campbell, J. D. ;
Spackman, D. E. ;
Sullivan, S. D. .
ALLERGY, 2010, 65 (09) :1141-1148
[7]  
Campbell Jonathan D, 2014, Ann Am Thorac Soc, V11 Suppl 2, pS105, DOI 10.1513/AnnalsATS.201309-295RM
[8]  
Dal Negro RW, 2011, EUR ANN ALLERGY CLIN, V43, P45
[9]   A 36-Month Study on the Cost/Utility of Add-On Omalizumab in Persistent Difficult-to-Treat Atopic Asthma in Italy [J].
Dal Negro, Roberto Walter ;
Tognella, Silvia ;
Pradelli, Lorenzo .
JOURNAL OF ASTHMA, 2012, 49 (08) :843-848
[10]   The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients:: adaptation of INNOVATE to Sweden [J].
Dewilde, S. ;
Turk, F. ;
Tambour, M. ;
Sandstrom, T. .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (09) :1765-1776